NERV
NASDAQMinerva Neurosciences
$5.65
+0.85 (+17.71%)
2026-02-09 00:00
Healthcare
Biotechnology
--
--
Market Cap
$26.9M
P/E Ratio
N/A
52W Low
52W High
$1.93
$12.46
Volume
300K
Analyst Rating
Hold
Target: $4
2 Analyst Ratings
Strong Buy
0
Buy
0
Hold
2
Sell
0
Price Target Range
Low: $4
Avg: $4
High: $4
About Minerva Neurosciences
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neur...
Employees
8
Website
minervaneurosciences.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2024 | N/A% | |||
| 2023 | N/A% | |||
| 2022 | N/A% | |||
| 2021 | N/A% | |||
| 2020 | 4.5% |